Health Care • Ophthalmic Goods
$0.83 ▼ -0.03
(-3.43%)
MKT CAP: $7.2M • VOL: 201.4K
52W L $1 52W H $2
ROARABLE / RQD
D- • 42/100
PIOTROSKI
4 / 9
LUCY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.7M | $1.6M | $1.2M |
| YoY Revenue Growth % | +62.6% | +42.0% | — |
| Gross Profit | $567.5K | $215.2K | — |
| Gross Margin % | 21.3% | 13.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.6M | -$7.8M | -$6.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.3M | -$6.7M | -$5.8M |
| Capital Expenditures (CapEx) | $72.5K | $62.2K | — |
| Free Cash Flow (FCF) | -$7.3M | -$6.8M | -$5.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $6.5M | $2.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.1M | $9.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LUCY.